Breaking AI & Tech News Analyzed

Mexico’s art world is in uproar after an agreement with Banco Santander to export a landmark segment of the Gelman collection to Spain. The collection, hailed as one of the most significant assemblages of 20th‑century Mexican art, features masterpieces by Frida Kahlo, Diego Rivera, Rufino Tamayo, José Clemente Orozco, María Izquierdo and David Alfaro Siqueiros. Approximately 400 cultural professionals have signed an open letter demanding clarity from the Mexican government about the fate of the works, especially those by Kahlo that the state has designated as an "artistic monument". Historian Francisco Berzunza warned that Kahlo is "the most important artist in the history of our country" and that her works should remain accessible in Mexico. The disputed batch comprises 160 paintings, sketches and photographs originally owned by collectors Jacques and Natasha Gelman and purchased by the Zambrano family in 2023. Under the Santander deal, the pieces—currently on public display in Mexico for the first time in two decades—are slated to travel to Spain this summer to become a centerpiece of the new Faro Santander cultural centre. Santander’s announcement promised to handle "conservation, research and exhibition" of the collection, yet it omitted the duration of the Spanish stay. The bank’s director, Daniel Vega Pérez de Arlucea, later told El País that the legislation governing the works is "flexible" and that the collection would enjoy a "permanent presence" at the centre, intensifying concerns. Mexican officials have attempted to reassure the public. President Claudia Sheinbaum stated, "Our desire is for the collection to remain in Mexico," while Culture Minister Claudia Curiel de Icaza emphasized that the export is only temporary and that the artworks are expected to return by 2028. Santander also issued a statement insisting the deal does not constitute a sale or permanent removal. Nevertheless, critics argue the contract is ambiguous. The agreement, viewed by the Guardian, allows Faro Santander to retain control of the collection at any point between June 2026 and 30 September 2030, with the possibility of extensions by mutual consent. Such language fuels fears that the pieces could become effectively permanent fixtures abroad. Legal experts note that Mexican law protects works declared national artistic monuments, mandating that they may leave the country only temporarily and that the National Institute of Fine Arts and Literature (Inbal) is responsible for their repatriation. With Inbal owning just four of Kahlo’s roughly 150 pieces, many fear the deal undermines the protective framework. Berzunza summed up the stakes: "If the works were not to return, a fundamental part of this artist’s body of work – and her history – would be lost. These pieces are essential to telling her story and to understanding our identity as Mexicans."

When Corentin Roudaut arrived in Paris a decade ago, he swapped his student‑era bike for a car, daunted by the city’s traffic and lack of cyclist protection. After a protected lane opened on Boulevard Voltaire in the 11th arrondissement, he reclaimed his two‑wheel commute and now volunteers with the cycling advocacy group Paris en Selle, witnessing a city that has shed its car‑centric image.Roudaut notes that the shift “started slowly but really accelerated in the last ten years,” with a growing network of bike routes that is becoming safe and nearly complete in many districts.Mayor Anne Hidalgo’s 12‑year agenda reshaped Paris’s urban fabric. Since taking office in 2014, her administration planted 155,000 trees, created several hundred kilometres of segregated bike lanes, pedestrianised 300 school streets, and banned cars from the banks of the Seine. Former parking spaces have been turned into green plazas and café terraces, reducing the risk of children being hit while walking to school.As Hidalgo departs on Sunday, her legacy is touted as a blueprint for progressive European cities, especially as some national governments retreat from green initiatives.Nevertheless, the reforms have sparked pushback. Motorists object to the loss of road space, and recent referendums on higher parking charges for SUVs and further school‑street pedestrianisation suffered low voter turnouts. Right‑wing mayoral candidate Rachida Dati described the new public‑space regime as “anxiety‑inducing,” though she stopped short of promising a reversal.In a candid interview, Hidalgo described the Seine‑bank pedestrianisation as “a tough battle” that, once won, left residents reluctant to revert to car traffic. She highlighted a generation of children who have never known cars on those riverbanks, prompting awe‑filled reactions from visitors.Urban scholars attribute the rapid change to Paris’s tight administrative boundaries, which limit suburban influence on city transport decisions, and to groundwork laid by previous mayors. Yet they stress that political courage was essential to implement measures that inconvenienced drivers while delivering social and environmental benefits.Environmental epidemiologist Audrey de Nazelle of Imperial College London, a Paris native, praised the transformation as “fabulous” and warned that many cities lack the bravery to pursue similar legacies.A recent report placed Paris among 19 global cities that cut two major toxic air pollutants between 2010 and 2024. While Brussels and Warsaw saw faster declines in fine‑particle matter, London outpaced Paris in reducing nitrogen‑dioxide levels.By contrast, Berlin—despite opening a new inner‑city motorway and scrapping 30 km/h speed limits on key streets—still records a higher share of cyclists than Paris.Transport researcher Giulio Mattioli argues that Paris simply needed to add bike lanes to unlock latent demand, noting that the city started from a lower baseline but quickly caught up with peers.However, the transformation remains uneven. The extensive suburbs continue to be dominated by cars, hemmed in by the 35 km Boulevard Périphérique ring road. Analyst Jean‑Louis Missika of think‑tank Terra Nova stresses that “as long as this motorway encircles Paris, the Greater Paris metropolis will remain an administrative construct devoid of urban reality.” He calls for dismantling or repurposing the ring road to achieve a truly post‑car metropolis.

The Accelerator's Withdrawal: A Signal of Loss of ConfidenceDelve's relationship with Y Combinator has officially ended following a series of damaging allegations regarding compliance and data security. This severance marks a significant blow to the startup's credibility, compounded by the distancing actions of other major investors like Insight Partners.The Catalyst: Anonymous Allegations and Data BreachesThe controversy stems from an anonymous Substack campaign by "DeepDelver," which accused the company of misleading clients about regulatory compliance and passing off open-source tools as proprietary technology. These claims were further fueled by a security researcher's ability to access sensitive Delve data and a malware incident involving a customer, LiteLLM.YC's Response: Delve was removed from the accelerator's portfolio directory, with COO Selin Kocalar confirming the split on X.Insight Partners: The firm initially deleted posts about its investment but later restored the primary blog entry.The Defense: A Coordinated Attack or Operational Failure?In a bid to set the record straight, Delve's leadership team, including CEO Karun Kaushik, claims the attacks are a coordinated smear campaign orchestrated by an attacker who exfiltrated internal data. They argue that the "evidence points to a malicious attack rather than a genuine whistleblower."However, the company also acknowledged "growing too fast and falling short of our own standard." To mitigate the damage, Delve has hired a cybersecurity firm, offered complimentary re-audits to customers, and clarified that their open-source usage is compliant with Apache 2.0 licensing.Future Outlook: Rebuilding Trust in a Fragile EcosystemThe departure from Y Combinator suggests that the startup's growth trajectory is now in jeopardy. For a compliance-focused company, trust is the primary currency; the current allegations threaten to devalue this currency permanently. The coming months will determine if Delve can survive this reputational crisis or if it will become a cautionary tale in the compliance tech sector.

The World Health Organisation (WHO) has issued a stern warning against the ongoing US-Israeli attacks on Iranian healthcare facilities, amid the escalating conflict. The organisation's chief, Tedros Adhanom Ghebreyesus, reported that over 20 attacks on healthcare facilities in Iran have been verified since March 1, resulting in at least nine deaths, including an infectious diseases health worker and a member of the Iranian Red Crescent Society.The Pasteur Institute in Tehran, one of the oldest research and health facilities in the country, has sustained significant damage and was rendered unable to continue delivering health services. Iranian Ministry of Health spokesperson Hossein Kermanpour shared images of the heavily damaged building on social media, with parts of the facility reduced to rubble.Despite the attacks, Iran's ISNA news agency reported that the services of the Pasteur Institute have not been interrupted, and vaccine and serum production would continue. The WHO chief emphasised that the Institute plays a crucial role in protecting and promoting population health, particularly in emergencies.The attacks have not been limited to the Pasteur Institute. The WHO has reported damage to other healthcare facilities, including the Delaram Sina Psychiatric Hospital and the Tofigh Daru pharmaceutical facility, with no casualties reported. An explosion near the Imam Ali Hospital in Khuzestan province led to the facility's evacuation and cessation of services.Tedros stressed that humanitarian workers, ambulances, relief supplies, and humanitarian facilities must be respected and protected under international law. The Geneva Conventions, agreed upon after World War II, designate healthcare facilities as protected locations.The Iranian Red Crescent Society reported that a warehouse belonging to the organisation was targeted, destroying two-wheeled relief containers and two buses and relief vehicles. According to the organisation, 307 health, medical, and emergency care facilities have been damaged in the war.

In a viral trend on TikTok, Londoners are reviewing upmarket bakeries and cafes in their neighborhoods, sparking conversations about gentrification and the changing face of local businesses.Moses Combe, a 21-year-old from north London, started a series of videos called the 'Endz Department for Research', where he reviews upscale cafes that he wouldn't normally visit. His goal is to investigate the changes happening in his own backyard. Combe's review of Jolene, a bakery he describes as 'giving Gail's Pro Max', comes to £14.20. He enjoys the sausage roll, saying 'They did not skimp out with that sausage, bro.'Combe isn't alone in his reviews. Kobi Coker, a 27-year-old comedian and educator, also reviews 'gentrified' spaces. He says his videos exploring these areas weren't initially intentional but were sparked by noticing new, upmarket establishments opening up on his road during his daily commute. Coker has reviewed the Dusty Knuckle bakery, Jolene, Gail's, and Pret, often joking about his experiences.The trend has led to discussions about gentrification and its impact on local businesses. Coker notes that while some new businesses bring new ideas, the problem is that long-time residents 'aren't necessarily able to participate in it.' Matthew Roberts, operations manager at Jolene, welcomes the attention, saying it's 'all very positive' and that they want to 'welcome absolutely everybody.'Other reviewers, like Daniel Poon, a 27-year-old content creator, review mainstream chains when they release products inspired by other cuisines. He reviewed Pret's ube drink, saying it didn't feel authentic to the original Filipino flavor. Poon appreciates chains' efforts to branch out and try new things, but also values diversity and trying different cuisines.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

Science is often seen as a dry and serious field, but does it have to be? A recent study published in Proceedings of the Royal Society B found that scientists deliver an average of only 1.6 jokes per presentation, with 66% generating only polite chuckles.The findings confirm previous research, including a randomized clinical trial conducted over 20 years ago by Timandra Harkness and Helen Pilcher under the guise of the Comedy Research Project. The study found that laughter levels failed to reach statistical significance, even when scientists attempted to incorporate humor into their talks.However, research suggests that humor can be an effective tool in science communication. A 2025 study called Wit Meets Wisdom found that humor can boost credibility and likability, making researchers seem more trustworthy and their findings less likely to be disputed.Helen Pilcher, a science writer and author, argues that scientists should not be afraid to adopt a more playful tone when communicating their research. By incorporating humor, scientists can build cohesion and foster a sense of shared perspective with their audience.Pilcher suggests that scientists can use humor to make their research more engaging and memorable, without having to convert it into standup comedy. By doing so, scientists can make their research more accessible and enjoyable for a wider audience.

President Donald Trump has unveiled a bold budget request, seeking $1.5 trillion for military spending, a nearly 40% increase from the previous year. This ambitious proposal underscores the White House's priorities, emphasizing military strength and law enforcement.The budget request, while not legally binding, sets the stage for intense congressional negotiations. It includes a proposed $455 billion increase over fiscal year 2026, separate from an emergency request of $200 billion for the US-Israeli conflict with Iran.The plan involves significant shifts in funding, with $73 billion in cuts to domestic programs, including initiatives to counter climate change, boost renewable energy, and support equality and access in housing, education, and healthcare. Instead, funding would be redirected to projects such as Trump's Golden Dome missile defense system, critical minerals investment, US shipbuilding, and troop salary increases.Trump's proposal also emphasizes immigration enforcement, calling for continued funding for the Department of Homeland Security and Immigration and Customs Enforcement to support his mass deportation campaign. The request includes a 13% increase for the Department of Justice, focusing on violent crime.The budget plan faces challenges, including a potential deadlock in Congress over funding for ICE and Customs and Border Patrol. The administration suggests passing the budget through a mechanism known as reconciliation, which could be achieved with a simple majority in Congress.The US military expenditure has steadily increased, reaching $997 billion in 2024, according to the Stockholm International Peace Research Institute. The country consistently spends more on its military than the next nine countries combined, raising questions about priorities in defense and domestic spending.